December 4, 2025 saw the unveiling of the annual authoritative ranking — 2025 PE Daily China Life Science Venture 50 (VENTURE 50), jointly launched by Zero2IPO Group and PE Daily. Standing out from numerous candidates, Andao Pharma has successfully secured a spot among the top 50 enterprises.

As an innovative drug developer focusing on hematology and oncology, we uphold our mission: Cherish humanity, respect science, and benefit patients. We devote ourselves to advancing cutting-edge technologies and pursuing original innovation. This recognition represents the industry’s high affirmation and encouragement of our R&D strengths, innovative strategies and growth potential.

We have built a differentiated therapeutic pipeline centered on unmet clinical needs, striving to develop globally competitive novel medicines. This honor belongs to every Andao team member who stays committed to research and exploration. It also would not have been possible without the long-standing trust and support from our partners and investors.

Moving forward, we will take this achievement as new momentum to further accelerate clinical progress of our core pipeline. We aim to deliver high-quality innovative outcomes to patients, the industry and society, and continuously contribute to advancing human health.